Mr. Soumitra Moulick, TCG Lifesciences Pvt. Ltd., India
Mr. Soumitra Moulick, Lead Scientist at TCG Lifesciences Pvt. Ltd., brings over 18 years of expertise in drug discovery research, with impactful contributions in antimicrobial, anti-inflammatory, and anticancer therapeutics. Currently pursuing a PhD at NIT Raipur, he has published peer-reviewed papers and is engaged in an ICMR-funded project on antibiotic-resistant E. coli. His work has supported over 15 global collaborations with pharmaceutical leaders, earning recognition including a best poster award at IIIT Allahabad. His consistent commitment to innovation and translational science underscores his suitability for the Best Researcher Award.
Profile
Scopus
🎓 Early Academic Pursuits
Mr. Soumitra Moulick embarked on his academic journey with a Master’s degree from a reputed Indian university, laying a strong foundation in life sciences and pharmacological research. From the beginning, his keen interest in drug discovery and therapeutic development drove him to pursue in-depth studies in microbiology, pharmacology, and biochemistry. His academic dedication was further demonstrated when he enrolled in a PhD program at the prestigious National Institute of Technology (NIT), Raipur, where he continues to explore advanced research in antibacterial drug discovery. His early education equipped him with a robust scientific mindset and set the stage for a dynamic career in the pharmaceutical sector.
🧪 Professional Endeavors
Mr. Moulick has devoted over 18 years of his professional life to TCG Lifesciences Pvt. Ltd., Kolkata, one of India’s leading Contract Research Organizations (CROs). Rising through the ranks, he currently serves as a Lead Scientist in the In-vitro Pharmacology Department. In this role, he has led and collaborated on more than 15 drug discovery projects, targeting diseases in the therapeutic areas of oncology, infectious diseases, and inflammation.
His work spans protocol development, in-vitro screening, target validation, and assay optimization. Mr. Moulick has worked closely with world-renowned pharmaceutical companies such as Pfizer, Roche, Takeda, Grunenthal, MMV, and DNDi, showcasing his ability to integrate scientific rigor with industry demands. His career at TCG Lifesciences stands as a testament to his commitment, technical excellence, and leadership in translational research.
🔬 Contributions and Research Focus
Mr. Moulick’s primary research interests lie in antimicrobial resistance (AMR), anti-inflammatory therapeutics, and oncology drug discovery. His doctoral research focuses on antibiotic-resistant Escherichia coli, a major causative agent of urinary tract infections. This work is supported by the Indian Council of Medical Research (ICMR) under Grant No. DDR/IIRP23/0569.
He has already published two peer-reviewed research articles in reputed journals such as Microbial Drug Resistance and Microbial Pathogenesis. Despite the limitations on publishing often faced in CRO environments, Mr. Moulick has successfully balanced industry confidentiality with academic contribution. His scientific research emphasizes innovation, with a focus on identifying novel molecular targets, validating high-throughput screening methodologies, and exploring natural and synthetic compound libraries for drug efficacy.
🏅 Accolades and Recognition
Mr. Moulick’s contributions have not gone unnoticed. His poster presentation at the International Webinar cum Workshop on Recent Developments in Applied Biotechnology (organized by IIIT Allahabad) was honored with a Best Poster Award, reflecting the academic community’s recognition of his impactful research.
One of his recent publications received a provisional selection for the “Best Researcher Award”, further validating the significance and originality of his scientific output. In addition to this, he is currently in the process of contributing a book chapter, and he has one patent under review, indicating his continued engagement in knowledge creation and technology transfer.
🌍 Impact and Influence
Over nearly two decades, Mr. Moulick has significantly influenced both industry and academic research through his extensive project experience and collaborative spirit. His ability to work with global pharmaceutical giants has not only enhanced the credibility of Indian CROs but also brought innovative therapeutic candidates closer to clinical application.
His research on antibiotic resistance has real-world implications, particularly in the context of rising multidrug-resistant infections. By identifying alternative treatment strategies and molecular targets, Mr. Moulick’s work contributes meaningfully to public health and global medicine. His influence extends across laboratories, boardrooms, and academic institutions, as he frequently engages in collaborative projects that bridge academia and industry.
🌟 Legacy and Future Contributions
Looking ahead, Mr. Moulick is poised to further strengthen his contributions to drug discovery and biomedical innovation. His future endeavors include completing his PhD with a high-impact third publication, finalizing his patent application, and authoring a comprehensive book chapter that can serve as a resource for young researchers and professionals.
He aims to mentor early-career scientists in preclinical research and build a legacy of scientific excellence, collaboration, and integrity. With a vision to drive innovative, affordable, and accessible therapeutics, Mr. Moulick is committed to being a catalyst for change in the Indian and global pharmaceutical landscape.
His unique blend of academic rigor, industrial experience, and collaborative mindset makes him a valuable contributor to the scientific community, and his nomination for the Best Researcher Award is both timely and well-deserved.
Publication Top Notes
Author: S., Moulick, Soumitra, D.N., Roy, Dijendra Nath
Journal: Microbial Pathogenesis
Year: 2025
Bioflavonoid Baicalein Modulates Tetracycline Resistance by Inhibiting Efflux Pump in Staphylococcus aureus
Author: Soumitra Moulick and Dijendra Nath Roy
Journal: Microbial Drug Resistance
Year: 2024